REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs
- Written by PR Newswire
![]() |
Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services
BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service for human induced pluripotent stem cells (iPSCs)....
Read more: REPROCELL Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs















